Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial

Key Points

Patient-reported outcomes revealed significant improvements with durvalumab compared to placebo in small-cell lung cancer treatment.
The results showed a notable enhancement in quality of life metrics—highlighting the benefits of durvalumab.
Observational analysis conducted after concurrent chemoradiotherapy to assess treatment effects on patients' experiences and quality of life.
This trial emphasizes the importance of integrating patient-reported outcomes in assessing the efficacy of cancer treatments.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Phase 3 trial compares patient-reported outcomes of durvalumab versus placebo after chemoradiotherapy, indicating significant benefits for patients.

No takes yet. Share an insight, caveat, or question.

Novello et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share